8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) 240mg every two weeks or 480 mg every four weeks for the adjuvant treatment of urothelial carcinoma (UC) patients at high risk of recurrence after radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status. 23 August 2021
Positive 12-week results from the Phase III ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine have been published in the prestigious New England Journal of Medicine (NEJM). 21 August 2021
AstraZeneca has announced positive top-line results from a key Phase III trial of its injectable antibody therapy for COVID-19, AZD7442. 21 August 2021
Months after the USA granted approval to Roche and Regneron’s antibody cocktail for COVID-19 disease, the UK’s medicines regulator has followed suit. 21 August 2021
UK-based flu specialist Seqirus, a business unit of Australia’s CSL Limited, today announced plans to accelerate the development of its next generation of messenger RNA (mRNA) vaccine technology, self-amplifying messenger RNA (sa-mRNA), with the creation of a dedicated sa-mRNA program and senior leadership appointment. 20 August 2021
Australia’s Therapeutic Goods Administration (TGA) today granted provisional approval to the local subsidiary of UK pharma major GlaxoSmithKline for its COVID-19 treatment - sotrovimab (trade name Xevudy) - making it the second COVID-19 treatment to receive regulatory approval in Australia. 20 August 2021
Gilead Sciences has announced that the company’s Marketing Authorization Application (MAA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, has been fully validated and is now being evaluated by the European Medicines Agency (EMA). 20 August 2021
US drugmaker Alexion Pharmaceuticals revealed today that it is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). 20 August 2021
Comirnaty, the COVID-19 vaccine from Pfizer and BioNTech, is 86% effective in preventing infection among those aged 60 and older after a third dose, according to an Israeli study. 19 August 2021
Adding to US regulatory clearance in March this year, US pharma major Bristol Myers Squibb has now won conditional approval for its a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy Abecma (idecabtagene vicleucel; ide-cel) from the European Commission. 19 August 2021
Research from industry analyst GlobalData shows that domestic drug developers in China are leading the way in CAR-T cell therapy trials, with 337 company-sponsored studies underway. 19 August 2021
Shares of China-headquartered Adagene were down 3.9% at $17.10 in early trading, despite the company today announcing that it has entered into a third clinical trial collaboration and supply agreement with US pharma giant Merck & Co 19 August 2021
While people in many parts of the world wait in the hope of receiving their first shot of a COVID-19 vaccine, Americans are to be offered their third dose in an attempt to boost immunity to the virus. 19 August 2021
US clinical-stage biotech AzurRx BioPharma saw its shares rocket almost 32% to $0.69 yesterday, after it reported some positive mid-stage trials results for its cystic fibrosis candidate MS1819. 19 August 2021
Privately-held Irish-American company Shorla Pharma has announced a partnership with Eversana to support the launch and commercialization of its oncology portfolio. 18 August 2021
The China National Medical Products Administration (NMPA) has granted Qarziba (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above, said the drug’s developers, UK-based EUSA Pharma and China’s BeiGene, whose shares rose 1.8% to $286.64 on the news. 18 August 2021
US biotech Qualigen Therapeutic' shares tumbled more than 22% to $1.30 yesterday, after it announced its intention to prioritize its focus to its oncology pipeline that includes QN-247 and RAS-F. 18 August 2021
Swedish company Alligator Bioscience saw its shares gain 16.4% to 6.68 Swedish kronor by early afternoon, when it revealed a research and license agreement with Finnish firm Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. 18 August 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.